Benzinga·2025-09-18 12:57Core Insights - Novo Nordisk presented data from the STEER real-world study at the ESC Congress 2025, comparing the cardiovascular risks of Wegovy (semaglutide) and Eli Lilly's tirzepatide in patients with obesity and established cardiovascular disease (CVD) without diabetes [1]. Group 1: Cardiovascular Risk Reduction - Wegovy demonstrated a 57% greater risk reduction for major adverse cardiovascular events (MACE) compared to tirzepatide in patients with obesity and CVD, with no treatment gaps exceeding 30 days [2]. - In the study, 15 cardiovascular events (0.1%) were recorded with Wegovy, while 39 events (0.4%) were noted with tirzepatide, with average follow-up durations of 3.8 months for Wegovy and 4.3 months for tirzepatide [3]. Group 2: Overall Treatment Efficacy - Regardless of treatment gaps, Wegovy showed a 29% risk reduction for heart attack, stroke, and death from any cause compared to tirzepatide, with an average follow-up of 8.3 months for Wegovy and 8.6 months for tirzepatide [4]. - A total of 56 cardiovascular events (0.5%) were recorded with Wegovy, compared to 83 events (0.8%) with tirzepatide [4][5]. Group 3: Future Developments - Novo Nordisk plans to seek U.S. regulatory approval for a high-dose version of Wegovy, which offers similar weight-loss potential as Eli Lilly's Zepbound, providing patients with additional treatment options [6]. - Following the announcement, Novo Nordisk's stock (NVO) rose by 7.63% to $62.64 in premarket trading [6].